Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $42.68 | 2 | 51.0% |
| Education | $41.01 | 3 | 49.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $24.37 | 1 | $0 (2018) |
| EMD Serono, Inc. | $18.31 | 1 | $0 (2023) |
| Stemline Therapeutics Inc. | $16.75 | 1 | $0 (2019) |
| Seattle Genetics, Inc. | $12.29 | 1 | $0 (2018) |
| Acrotech Biopharma LLC | $11.97 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $18.31 | 1 | EMD Serono, Inc. ($18.31) |
| 2021 | $11.97 | 1 | Acrotech Biopharma LLC ($11.97) |
| 2019 | $16.75 | 1 | Stemline Therapeutics Inc. ($16.75) |
| 2018 | $36.66 | 2 | Foundation Medicine, Inc. ($24.37) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $18.31 | General |
| Category: Oncology | ||||||
| 05/03/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2019 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Education | In-kind items and services | $16.75 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 09/06/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 1,304 | 47,734 | $2.4M | $755,685 |
| 2022 | 41 | 1,933 | 84,800 | $5.2M | $1.7M |
| 2021 | 52 | 2,477 | 132,698 | $7.5M | $2.8M |
| 2020 | 55 | 2,448 | 133,192 | $7.2M | $2.5M |
All Medicare Procedures & Services
183 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 10,600 | $932,800 | $453,932 | 48.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 141 | 408 | $199,512 | $58,716 | 29.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 2,940 | $132,300 | $53,203 | 40.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 12 | 2,770 | $207,750 | $29,298 | 14.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 91 | 225 | $161,100 | $27,763 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 230 | 300 | $109,200 | $27,429 | 25.1% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 930 | $176,700 | $22,581 | 12.8% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 11 | 660 | $77,220 | $20,964 | 27.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 123 | 226 | $80,456 | $13,628 | 16.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $23,698 | $5,800 | 24.5% |
| J9030 | Bcg live intravesical instillation, 1 mg | Office | 2023 | 32 | 2,350 | $18,800 | $5,288 | 28.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 11 | 10,200 | $20,400 | $4,010 | 19.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 53 | $16,854 | $3,663 | 21.7% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2023 | 31 | 46 | $26,082 | $3,651 | 14.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 32 | 149 | $15,794 | $2,828 | 17.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 50 | 173 | $19,030 | $2,495 | 13.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 33 | 93 | $14,508 | $2,489 | 17.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 19 | 38 | $13,680 | $2,303 | 16.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 29 | 87 | $13,398 | $2,290 | 17.1% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 31 | 85 | $10,030 | $2,009 | 20.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 54 | 154 | $16,478 | $1,948 | 11.8% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 11 | 20 | $5,960 | $1,798 | 30.2% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 12 | 8,580 | $8,580 | $1,543 | 18.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 39 | 211 | $42,622 | $1,515 | 3.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 17 | 27 | $7,587 | $950.94 | 12.5% |
About Dr. Michael Wu, MD
Dr. Michael Wu, MD is a Hematology & Oncology healthcare provider based in Santa Cruz, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700850104.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Wu, MD has received a total of $83.69 in payments from pharmaceutical and medical device companies, with $18.31 received in 2023. These payments were reported across 5 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($42.68).
As a Medicare-enrolled provider, Wu has provided services to 8,162 Medicare beneficiaries, totaling 398,424 services with total Medicare billing of $7.7M. Data is available for 4 years (2020–2023), covering 183 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Santa Cruz, CA
- Active Since 02/14/2006
- Last Updated 12/07/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700850104
Products in Payments
- FOUNDATIONONE (Device) $24.37
- BAVENCIO (Drug) $18.31
- ELZONRIS (Drug) $16.75
- ADCETRIS (Biological) $12.29
- BELEODAQ (Drug) $11.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Santa Cruz
Dr. Michael Yen, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $21,862
Dr. Amir Tabatabai, M.d, M.D
Hematology & Oncology — Payments: $2,393
Rohan Ahluwalia
Hematology & Oncology — Payments: $1,859
Glenn Wong, Do, DO
Hematology & Oncology — Payments: $805.72
Simranjit Sekhon, M.d, M.D
Hematology & Oncology — Payments: $695.43
Dr. Janet Wang
Hematology & Oncology — Payments: $416.14